Abstract
Prostate cancer is the second leading cause of male cancer mortality in Brazil. In recent years, prostate-specific membrane antigen (PSMA)-targeted radioligand therapy has emerged as a promising option for patients suffering from mCRPC and do not respond to previously recommended therapies. Indeed, 45-60% of patients with mCRPC respond to 177Lu-PSMA therapy as demonstrated by several clin…